Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: CYP1A2 – a novel genetic marker for early aromatase inhibitor response in the treatment of breast cancer patients

Fig. 2

a-d Kaplan-Meier estimates of event-free survival in relation to CYP1A2 and CYP19A1 genotypes in AI-treated breast cancer patients with ER+ tumors are illustrated. LogRank P-values are presented for the entire follow-up time. In Fig. 2 a, b, and d, 5-year adjusted HRs are also presented. a CYP1A2 rs762551. The main association between CYP1A2 rs762551 any C-allele and early events was observed within 5 years of inclusion. b CYP19A1 rs4646. No significant association between CYP19A1 rs4646 and early events was observed. c Combinations of CYP1A2 rs762551 and CYP19A1 rs4646 genotype. Patients with any C-allele of CYP1A2 rs762551 and C/C genotype of rs4646 had a worse prognosis compared to patients with the three other genotype combinations. d CYP1A2 rs762551 any C-allele and rs4646 C/C. A combined variable of any C-allele of CYP1A2 rs762551 and C/C genotype of rs4646 was created and patients with this combination had a worse prognosis compared to patients with any other genotype. The main association was observed within 5 years of inclusion

Back to article page